Combating P-glycoprotein-Mediated Multidrug Resistance Using Therapeutic Nanoparticles

Author(s): Qiu Zhang, Fei Li

Journal Name: Current Pharmaceutical Design

Volume 19 , Issue 37 , 2013

Become EABM
Become Reviewer
Call for Editor


The development of multidrug resistance (MDR) to chemotherapy is a major obstacle for the successful treatment of cancer. A number of mechanisms have been postulated to account for MDR in cancer. The most common and best-studied mechanism of resistance is mediated through the drug efflux protein P-glycoprotein (P-gp), which is overexpressed in drug-resistant cancer cells and is responsible for the removal of many chemotherapeutic agents. Therapeutic nanoparticles (NPs) have emerged as an innovative and promising option to combat P-gp-mediated MDR and have shown enhanced therapeutic efficacy and reduced toxicity compared to their small molecule counterparts. This review focuses on recent studies using therapeutic NPs to circumvent P-gp-mediated MDR in cancer therapy. The advantages and strategies by which therapeutic NPs were used to overcome P-gp-mediated MDR in cancer are discussed.

Keywords: P-glycoprotein, multidrug resistance, nanotechnology, drug delivery, therapeutic nanoparticles, cancer chemotherapy.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [6655 - 6666]
Pages: 12
DOI: 10.2174/1381612811319370009
Price: $65

Article Metrics

PDF: 33